1. Home
  2. PRME vs RGR Comparison

PRME vs RGR Comparison

Compare PRME & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$2.89

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo Sturm Ruger & Company Inc.

RGR

Sturm Ruger & Company Inc.

HOLD

Current Price

$38.88

Market Cap

617.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
RGR
Founded
2019
1949
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Ordnance And Accessories
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
617.8M
IPO Year
2022
1994

Fundamental Metrics

Financial Performance
Metric
PRME
RGR
Price
$2.89
$38.88
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$7.56
$43.00
AVG Volume (30 Days)
2.8M
97.2K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
1.07%
EPS Growth
18.18
N/A
EPS
N/A
0.01
Revenue
$4,632,000.00
$546,057,000.00
Revenue This Year
$7.06
$2.38
Revenue Next Year
$47.01
N/A
P/E Ratio
N/A
$3,888.00
Revenue Growth
55.28
1.94
52 Week Low
$1.40
$28.33
52 Week High
$6.94
$48.21

Technical Indicators

Market Signals
Indicator
PRME
RGR
Relative Strength Index (RSI) 41.40 42.98
Support Level $2.68 $38.60
Resistance Level $3.72 $38.89
Average True Range (ATR) 0.28 0.87
MACD -0.00 -0.02
Stochastic Oscillator 21.98 15.32

Price Performance

Historical Comparison
PRME
RGR

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About RGR Sturm Ruger & Company Inc.

Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.

Share on Social Networks: